Cognitive function paradigms: implications of neurophysiological studies of dopamine stimulants for Tourette syndrome and comorbid attention-deficit hyperactivity disorder.
Walters
J R
JR
Neurophysiological Pharmacology Section, Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
Ruskin
D N
DN
Baek
D
D
Allers
K A
KA
Bergstrom
D A
DA
D001289:Attention Deficit Disorder with Hyperactivity / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D003072:Cognition Disorders / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D018491:Dopamine Agonists / Q000627:therapeutic use*; D006801:Humans; D005879:Tourette Syndrome / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology
D018491:Dopamine Agonists